Abstract 987P
Background
We aimed to evaluate the safety and efficacy of lenvatinib in Korean population under real-world practice.
Methods
Patients were prospectively entered at 29 clinical sites through an observational post-marketing study in Korea, funded by Eisai. Patients were treated with lenvatinib according to the approved indication of uHCC. For safety analysis, Adverse Drug Reactions (ADRs) were collected. ADR was defined as AEs where the causal relationship with lenvatinib was not 'unlikely'. The efficacy was assessed by investigators as completed response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). Objective response rate (ORR) was defined as CR or PR in the efficacy analysis set. Statistical analysis was conducted to identify which demographic and clinical factors were related to ORR.
Results
658 patients were included in the safety analysis set. The mean daily dose was 7.8mg/day and 10.1mg/day in patients with a body weight of < 60kg and ≥ 60kg. The relative dose intensity related to tolerance was 97% and 84%, respectively. ADRs > grade 3 were reported in 1% (8/658). The most common ADRs > grade 3 were ‘palmar-plantar erythrodysaesthesia syndrome’ (0.3%, 2/658). In the efficacy analysis set, 513 patients were included. The results were as follows: CR, 1% (5/513); PR, 13% (66/513); SD, 45% (231/513); and PD, 41% (211/513). Among the demographic and clinical factors, ORR was significantly different depending on the total treatment duration (p <0.001).
Table: 987P
Objective response rate n (%) | No. of Subjects n (%) | p-value | |
Total treatment duration | |||
< 3 months | 12 (6) | 191 (38) | <0.001 |
3 months ∼ < 6 months | 21 (13) | 165 (32) | |
6 months ∼ < 9 months | 15 (19) | 78 (15) | |
9 months or above | 23 (30) | 76 (15) | |
Total | 71 (14) | 510 (100) |
Conclusions
Lenvatinib in Korean patients with uHCC was generally well tolerated. The efficacy of treatment varied significantly with regards to the total treatment duration. Patients with longer treatment duration showed higher ORR.
Clinical trial identification
E7080-M082-509
Editorial acknowledgement
We acknowledge the significant contribution of Prof. Kang in reviewing abstract.
Legal entity responsible for the study
Eisai Korea and the authors.
Funding
Eisai.
Disclosure
J.J. Kim: Other, Institutional, Project Lead: Eisai Korea. All other authors have declared no conflicts of interest.
Resources from the same session
1000P - Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC)
Presenter: Daniel Ahn
Session: Poster session 18
1001P - Patients’ prioritization of treatment goals in hepatocellular carcinoma (HCC): A global qualitative observational study (PERIDOT)
Presenter: Marcus-Alexander Wörns
Session: Poster session 18
1002P - Efficacy and safety of tislelizumab combined with TKIs and FOLFOX4-HAIC in conversion therapy of unresectable hepatocellular carcinoma
Presenter: Kai Tan
Session: Poster session 18
1003P - Efficacy and safety of triple combination therapy with transarterial chemoembolization (TACE), tyrosine kinase inhibitor (TKI), and immune checkpoint inhibitor (ICI) versus dual combination therapy in unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis
Presenter: Omar Maaño
Session: Poster session 18
1004P - Comparative efficacy of systemic sequential regorafenib after sorafenib or lenvatinib treatment failure for advanced hepatocellular carcinoma: A retrospective, multi-center, real-world study
Presenter: Danjun Song
Session: Poster session 18
1005P - Atezolizumab plus bevacizumab combined with transarterial chemoembolization and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma with high tumor burden
Presenter: Jiliang Qiu
Session: Poster session 18
1006P - Associations of online search trends and prescription trends for hepatocellular carcinoma drugs
Presenter: Philipp Berning
Session: Poster session 18
1007P - Network meta-analysis (NMA) of lenvatinib vs key comparators in first-line unresectable hepatocellular carcinoma (uHCC)
Presenter: David Trueman
Session: Poster session 18